Cingulate Inc.
CING · XNASCIK 1862150fmd_0JRZV6WSDDAX2MSV9GN874BECXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 23 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net interest income | – | – | – | – | 0 | (1) |
| Research and development | 5 | 8 | 9 | 15 | 9 | 10 |
| Operating income | (7) | (21) | (18) | (23) | (16) | (20) |
| Interest expense | 0 | 0 | 0 | 1 | 0 | 1 |
| Other non-operating income (expense) | (0) | (0) | (0) | (1) | 0 | – |
| Income before taxes | (7) | (21) | (18) | (24) | (17) | (22) |
| Net income | (7) | (21) | (18) | (24) | (17) | (22) |